Revolution Medicines (RVMD) Income towards Parent Company (2019 - 2026)

Revolution Medicines' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$240.4 million (up 65.53% YoY), while the FY2024 annual figure was -$600.0 million, down 36.31% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$453.8 million, down from $766.4 million in the prior quarter.
• The five-year high for Income towards Parent Company was $766.4 million in Q4 2025, with the low at -$453.8 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$116.0 million (2024), against an average of -$102.5 million.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company tumbled 192.58% in 2023, then jumped 494.0% in 2025.
• Revolution Medicines' Income towards Parent Company stood at -$56.5 million in 2022, then plunged by 192.58% to -$165.4 million in 2023, then retreated by 17.62% to -$194.5 million in 2024, then surged by 494.0% to $766.4 million in 2025, then slumped by 159.21% to -$453.8 million in 2026.
• Business Quant data shows RVMD's Income towards Parent Company at -$453.8 million in Q1 2026, $766.4 million in Q4 2025, and -$305.2 million in Q3 2025.